JIN Competitors

Stocks . USA . 
Stock . JIN MEDICAL INTERNATIONAL
ZJYL Stock   0.95  0.11  10.38%   
JIN MEDICAL INTERNATIONAL competes with Apogee Enterprises, Marfrig Global, BBB Foods, Eastman Kodak, and Ryanair Holdings; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing JIN MEDICAL competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of JIN MEDICAL to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out JIN MEDICAL Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of JIN MEDICAL competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of JIN MEDICAL's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.040.7910.10
Details
Intrinsic
Valuation
LowRealHigh
0.050.9110.22
Details
Naive
Forecast
LowNextHigh
0.010.649.95
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.801.301.81
Details

JIN MEDICAL Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between JIN MEDICAL and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of JIN and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of JIN MEDICAL INTERNATIONAL does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
GZITF
+ 0.8
MRRTY
GZITF
+ 0.73
SNCY
SNCY
+ 0.69
APOG
TBBB
+ 0.61
APOG
GZITF
+ 0.57
APOG
SNCY
+ 0.52
RYAAY
  
High negative correlations   
DKL
- 0.6
TBBB
DKL
- 0.52
SNCY
DKL
- 0.46
APOG
DKL
- 0.31
GZITF
DKL
- 0.21
RYAAY
DKL
- 0.18
MRRTY

Risk-Adjusted Indicators

There is a big difference between JIN Stock performing well and JIN MEDICAL Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze JIN MEDICAL's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

JIN MEDICAL Competitive Analysis

The better you understand JIN MEDICAL competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, JIN MEDICAL's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across JIN MEDICAL's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ZJYL APOG MRRTY TBBB KODK RYAAY SNCY GZITF DKL
 10.38 
 0.95 
JIN
 1.98 
 84.87 
Apogee
 5.12 
 3.08 
Marfrig
 0.26 
 34.16 
BBB
 18.60 
 6.25 
Eastman
 1.88 
 43.79 
Ryanair
 2.33 
 14.05 
Sun
 0.00 
 0.58 
Yuexiu
 1.02 
 39.59 
Delek
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Risky
Very steady
Unstable
Very steady
Not too volatile
Abnormally volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
OK
Weak
Very Weak
Weak
OK
OK
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Very Low
Low
Low
About Average
Very Small
Low
About Average
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Hold
Not Available
Not Available
Strong Sell
Strong Buy
Strong Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Buy
Strong Sell
Hold
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Current Ratio
N/A
1.82
1.28
N/A
2.48
1.08
1.1
0.72
0.39
Net Asset
32.9 M
884.06 M
48 B
14.96 B
2.35 B
17.18 B
1.62 B
35.66 B
1.64 B
Profit Margin
0.14
0.0758
0.0465
-0.0067
0.077
0.11
0.0425
0.35
0.13
EBITDA
3.44 M
178.83 M
9.91 B
2.43 B
169 M
3.06 B
226.24 M
2.94 B
370.28 M
Operating Margin
0.12
0.13
0.0822
0.0276
0.13
0.33
0.0496
0.43
0.15
Current Valuation
149.9 M
1.88 B
8.89 B
3.65 B
919.71 M
20.12 B
1.27 B
2.81 B
3.96 B
Price To Book
6.32
3.61
0.75
19.24
0.43
2.93
1.35
0.61
N/A
Retained Earnings
16.93 M
340.38 M
(3.93 B)
(5.96 B)
(495 M)
5.9 B
94.23 M
N/A
485.59 M
Current Asset
N/A
336.79 M
10.22 B
N/A
1.28 B
4.82 B
N/A
N/A
47.04 M
Five Year Return
N/A
2.01
N/A
N/A
N/A
N/A
N/A
N/A
10.36
Beta
N/A
0.97
0.53
N/A
3.65
1.39
1.49
0.81
2.1
Number Of Employees
245
4.4 K
31.78 K
21.92 K
4 K
27 K
2.96 K
2.01 K
25
Shares Outstanding
156.55 M
21.94 M
653.44 M
38.71 M
80.4 M
543.12 M
52.94 M
1.67 B
51.47 M
Cash Flow From Operations
3.11 M
204.15 M
9.03 B
3.14 B
38 M
3.16 B
174.12 M
2.57 B
225.32 M
Annual Yield
N/A
0.012
0.24
N/A
N/A
0.0176
N/A
0.12
0.11
Total Debt
4.11 M
106.19 M
23.68 B
11.91 B
495 M
2.75 B
697.78 M
13.22 B
1.72 B
Return On Equity
0.11
0.22
0.32
N/A
0.0685
0.19
0.0842
0.11
N/A
Z Score
N/A
N/A
1.0
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0403
0.11
0.0653
N/A
0.0393
0.0634
0.0378
0.0283
0.0766
Number Of Shares Shorted
1.09 M
918.16 K
N/A
3.27 M
4.85 M
7.81 M
3.7 M
N/A
628.3 K
Book Value Per Share
0.17
23.08
10.36
31.62
12.21
7.09
10.44
6.71
-2.45
Current Liabilities
N/A
177.38 M
8.08 B
N/A
459 M
3.37 B
N/A
N/A
20.69 M
Total Asset
32.9 M
884.06 M
48 B
14.96 B
2.35 B
17.18 B
1.62 B
35.66 B
1.64 B
Short Ratio
2.77
4.91
N/A
6.12
11.45
5.46
4.63
N/A
2.88
Debt To Equity
N/A
0.83
2.04
N/A
0.33
0.81
1.3
1.15
-35.06
Target Price
N/A
83.0
N/A
32.25
1.0
53.0
19.13
N/A
44.0
Last Dividend Paid
N/A
0.99
2.25
N/A
N/A
0.58
N/A
0.42
4.32
Shares Owned By Institutions
1.14
96.17
0.3
100.0
44.72
45.89
98.79
16.62
14.8
Market Capitalization
165.94 M
1.86 B
836.41 M
3.44 B
441.4 M
23.78 B
743.8 M
982.59 M
2.06 B
Price To Earning
N/A
81.0
2.19
N/A
232.67
16.27
15.79
7.22
12.25
Price To Earnings To Growth
N/A
1.57
N/A
N/A
N/A
3.63
0.61
N/A
0.77
Price To Sales
8.25
1.35
0.0087
0.0688
0.4
1.75
0.7
0.28
2.09
Net Income
2.88 M
99.61 M
4.34 B
(100.91 M)
75 M
1.92 B
72.18 M
1.46 B
126.24 M
Earnings Per Share
0.02
4.84
1.64
-0.15
0.7
1.85
0.83
0.11
2.82
Shares Owned By Insiders
75.84
1.83
N/A
N/A
21.98
N/A
4.6
44.24
67.22
Revenue
19.82 M
1.42 B
85.39 B
44.08 B
1.12 B
13.44 B
1.05 B
3.7 B
1.02 B
Working Capital
22.19 M
113.93 M
2.14 B
(4.56 B)
429 M
(573.5 M)
(147.23 M)
N/A
(14.32 M)
Cash And Equivalents
N/A
23.65 M
18.57 B
N/A
289 M
4.62 B
289.58 M
2.92 B
7.97 M
Cash Per Share
N/A
1.07
28.15
N/A
3.66
20.37
4.98
1.74
0.32
Gross Profit
6.36 M
302.36 M
17.2 B
N/A
173 M
791.1 M
245.38 M
2.25 B
309.61 M
Day Typical Price
0.99
85.3
3.05
34.21
6.11
43.73
14.16
0.58
39.72
Accumulation Distribution
0.14
0.0265
0.0292
0.0299
1.5 M
0.015
0.0298
N/A
0.0165
Market Facilitation Index
0.15
2.3
0.09
1.04
N/A
0.66
0.43
N/A
0.66
Daily Balance Of Power
(0.73)
0.7174
1.666667
0.0865
0.7313
1.227273
0.7442
0.0
(0.62)
Period Momentum Indicator
(0.11)
1.65
0.15
0.09
0.98
0.81
0.32
N/A
(0.41)
Rate Of Daily Change
0.9
1.02
1.05
1.0
1.19
1.02
1.02
1.0
0.99
Day Median Price
1.02
85.51
3.04
34.23
6.04
43.7
14.22
0.58
39.79
Price Action Indicator
(0.12)
0.19
0.12
(0.03)
0.7
0.5
(0.01)
N/A
(0.40)
Coefficient Of Variation
(703.56)
827.48
1047.69
1742.84
2169.02
1892.8
628.62
745.55
2243.19
Mean Deviation
5.27
1.85
2.38
1.66
2.36
1.55
2.64
0.8736
1.12
Jensen Alpha
(1.35)
0.1452
0.2247
0.0362
0.0967
0.0392
0.3909
0.3905
0.1235
Total Risk Alpha
(2.76)
(0.13)
(0.20)
(0.23)
(0.43)
(0.22)
0.0035
(0.08)
(0.23)
Sortino Ratio
N/A
0.1475
0.0538
9.0E-4
0.014
(0.01)
0.1432
N/A
(0.02)
Downside Variance
N/A
3.62
10.01
5.52
12.32
4.27
8.92
N/A
6.38
Standard Deviation
9.24
3.39
3.13
2.28
3.86
2.01
3.5
3.36
1.99
Kurtosis
20.3
28.7
0.5267
0.8144
8.0
0.2596
0.5815
62.43
21.2
Potential Upside
8.17
3.41
5.12
3.19
6.81
3.77
7.47
N/A
2.84
Treynor Ratio
(6.73)
0.1864
0.5335
0.1693
0.28
0.2005
0.4171
1.03
(0.21)
Maximum Drawdown
78.47
28.75
11.51
11.92
26.51
8.74
16.71
26.67
16.59
Variance
85.35
11.48
9.81
5.2
14.88
4.02
12.22
11.31
3.98
Market Risk Adjusted Performance
(6.72)
0.1964
0.5435
0.1793
0.29
0.2105
0.4271
1.04
(0.20)
Risk Adjusted Performance
(0.1)
0.1001
0.0805
0.0505
0.0433
0.0466
0.1294
0.1102
0.0402
Skewness
3.14
4.36
0.2709
(0.12)
0.0156
0.043
0.4674
7.89
(3.27)
Semi Deviation
N/A
1.6
2.56
2.17
3.38
1.94
2.58
N/A
2.37
Information Ratio
(0.16)
0.0829
0.0544
0.001
0.0128
(0.01)
0.1223
0.0959
(0.02)
Value At Risk
(11.20)
(2.93)
(5.00)
(3.51)
(3.69)
(3.25)
(4.50)
N/A
(1.44)
Expected Short fall
N/A
(2.28)
(3.08)
(1.76)
(2.87)
(1.52)
(3.09)
N/A
(1.09)
Downside Deviation
N/A
1.9
3.16
2.35
3.51
2.07
2.99
N/A
2.53
Semi Variance
N/A
2.56
6.55
4.7
11.46
3.75
6.63
N/A
5.63

JIN MEDICAL Competition Performance Charts

Five steps to successful analysis of JIN MEDICAL Competition

JIN MEDICAL's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by JIN MEDICAL INTERNATIONAL in relation to its competition. JIN MEDICAL's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of JIN MEDICAL in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact JIN MEDICAL's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to JIN MEDICAL INTERNATIONAL, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your JIN MEDICAL position

In addition to having JIN MEDICAL in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Raw Materials Thematic Idea Now

Raw Materials
Raw Materials Theme
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
View All  Next Launch
When determining whether JIN MEDICAL INTERNATIONAL is a strong investment it is important to analyze JIN MEDICAL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact JIN MEDICAL's future performance. For an informed investment choice regarding JIN Stock, refer to the following important reports:
How To Invest In JIN
Details
Is JIN Stock a good investment?
Details
What is JIN MEDICAL's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out JIN MEDICAL Correlation with its peers.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of JIN MEDICAL. If investors know JIN will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about JIN MEDICAL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of JIN MEDICAL INTERNATIONAL is measured differently than its book value, which is the value of JIN that is recorded on the company's balance sheet. Investors also form their own opinion of JIN MEDICAL's value that differs from its market value or its book value, called intrinsic value, which is JIN MEDICAL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because JIN MEDICAL's market value can be influenced by many factors that don't directly affect JIN MEDICAL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between JIN MEDICAL's value and its price as these two are different measures arrived at by different means. Investors typically determine if JIN MEDICAL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, JIN MEDICAL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY